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Abstract
Background Breast cancer patients with tumors that are
estrogen receptor (ER)-positive and/or progesterone receptor
(PR)-positive have lower risks of mortality after their diagnosis
compared to women with ER- and/or PR-negative disease.
However, few studies have evaluated variations in the risks of
breast cancer-specific mortality across ER/PR status by either
demographic or clinical characteristics.
Methods Using data from 11 population-based cancer
registries that participate in the SEER (Surveillance,
Epidemiology, and End Results) program, 155,175 women at
least 30 years old with a primary diagnosis of invasive breast
carcinoma from 1990 to 2001 were included in the study.
Associations between joint hormone receptor status and breast
cancer mortality risk within categories of diagnosis age,
diagnosis year, race/ethnicity, histologic tumor type, stage,
grade, size, and axillary lymph node status were evaluated using
the Cox proportional hazards model.
Results Compared to ER+/PR+ cases, elevations in risk of
mortality were observed across all subcategories of age at
diagnosis, ranging from 1.2- to 1.5-fold differences for ER+/PR-
cases, 1.5- to 2.1-fold differences for ER-/PR+ cases, and 2.1-
to 2.6-fold differences for ER-/PR- cases. Greater differences
were observed in analyses stratified by grade; among women
with low-grade lesions, ER-/PR- patients had a 2.6-fold (95%
confidence interval [CI] 1.7 to 3.9) to 3.1-fold (95% CI 2.8 to
3.4) increased risk of mortality compared to ER+/PR+ patients,
but among women with high-grade lesions, they had a 2.1-fold
(95% CI 1.9 to 2.2) to 2.3-fold (95% CI 1.8 to 2.8) increased
risk.
Conclusion Compared to women with ER+/PR+ tumors,
women with ER+/PR-, ER-/PR+, or ER-/PR- tumors
experienced higher risks of mortality, which were largely
independent of the various demographic and clinical tumor
characteristics assessed in this study. The higher relative
mortality risks identified among ER-/PR- patients with small or
low-grade tumors raise the question of whether there may be a
beneficial role for adjuvant chemotherapy in this population.
Introduction
Breast cancer patients with tumors that are estrogen receptor
(ER)-positive and/or progesterone receptor (PR)-positive have
lower risks of mortality after their diagnosis compared to
women with ER- and/or PR-negative disease [1-6]. Clinical tri-
als have also shown that the survival advantage for women
with hormone receptor-positive tumors is enhanced by treat-
ment with adjuvant hormonal and/or chemotherapeutic regi-
mens [7-9]. However, few studies have evaluated variations in
the risks of breast cancer-specific mortality across ER/PR sta-
tus by either demographic or clinical characteristics. The goal
of this study was to determine whether the greater relative risk
of breast cancer mortality observed among women with hor-
mone receptor-negative tumors was similar for those with dif-
ferent demographic characteristics, such as race/ethnicity,
age of cancer diagnosis, and year of cancer diagnosis, and for
those with different tumor characteristics, such as stage,
grade, tumor size, and histology, using data from Surveillance,
Epidemiology, and End Results (SEER), the population-based
tumor registry program of the National Cancer Institute (NCI).
Such an assessment may further elucidate the relationships
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between various prognostic indicators in breast cancer and
provide knowledge regarding the prognostic utility of ER/PR
status by demographic and clinical tumor characteristics.
Materials and methods
Patient selection
The cohort for this study was assembled using data from the
NCI's SEER program in the United States [10]. Since the early
1970s, the SEER program has collected incidence and sur-
vival data from population-based cancer registries spanning
five states and four metropolitan areas: Connecticut, Hawaii,
Iowa, New Mexico, Utah, San Francisco-Oakland (CA), Detroit
(MI), Seattle (Puget Sound) (WA), and Atlanta (GA). In 1992,
two population-based registries were added: San Jose-
Monterey (CA) and Los Angeles (CA). SEER began collecting
data on ER and PR status in 1990 for breast cancer cases.
Therefore, only data from 1 January 1990 through 31 Decem-
ber 2001 were included in this analysis.
We identified 209,276 women at least 30 years old with a pri-
mary diagnosis of invasive carcinoma of the breast as poten-
tially eligible subjects for this study. Women under the age of
30 years were excluded because the occurrence of breast
cancer among this age group is rare. Also excluded were
1,873 women whose breast carcinomas were diagnosed only
by autopsy or death certificate or whose diagnostic confirma-
tion of breast cancer was unknown. Because our primary anal-
ysis focused on associations between joint ER/PR status and
breast cancer-specific mortality, we excluded 50,291 women
missing tumor marker data for ER and/or PR (24% of the total
potentially eligible subjects). After the noted exclusions,
155,175 subjects were included in the study.
Women were categorized into four groups according to their
joint ER/PR status: ER+/PR+, ER+/PR-, ER-/PR+, and ER-/
PR-. The SEER registries provide information on age of diag-
nosis, year of diagnosis, and race/ethnicity. Data on other clin-
ical characteristics, such as tumor histology, grade, stage
(American Joint Committee on Cancer [AJCC] classification
system), and size, were also available. Additionally, SEER col-
lects data regarding the first course of cancer-directed surgi-
cal and radiation treatment interventions. However, SEER
does not make data on adjuvant chemotherapy or hormonal
therapy publicly available. SEER does not collect information
on other relevant factors such as reproductive history, anthro-
pometrics, medical history, family history of cancer, or cancer
screening history.
Outcome measures
Each SEER registry routinely updates vital status and follow-
up information for all patients with cancer. Survival time is cal-
culated in months by using the subject's date of breast cancer
diagnosis and one of the following: (a) date of death, (b) date
last known to be alive, or (c) the most recent follow-up cutoff
date. The follow-up cutoff date for the SEER data used in our
analysis was 31 December 2001. Because we were inter-
ested primarily in cause-specific mortality, our outcome of
interest was death due to breast cancer as indicated by cause-
of-death International Classification of Diseases codes.
Women who died of causes other than breast cancer were
censored at their date of death.
Statistical analysis
The statistical software program Stata for Macintosh version
9.1 (StataCorp LP, College Station, TX, USA) was used to
perform all analyses. Women with ER+/PR+ tumors served as
the referent category in all analyses because this was the larg-
est ER/PR subgroup. Associations between joint ER/PR
receptor status and breast cancer mortality risk within catego-
ries of diagnosis age (<50, 50 to 64, ≥65 years), diagnosis
year (3-year intervals: 1990 to 1992, 1993 to 1995, 1996 to
1998, and 1999 to 2001), race/ethnicity (non-Hispanic white,
terminology used is base on the SEER registries descriptions.
If you would prefer to change, OK. African-American, Native
American, Asian/Pacific Islander, Hispanic white), histologic
tumor type (ductal, lobular, ductal/lobular, inflammatory, muci-
nous, tubular, comedo, medullary, papillary), AJCC stage
grouping (I, II, III, IV), SEER grade (I, well differentiated; II, mod-
erately differentiated; III, poorly differentiated; IV, undifferenti-
ated), size (0 to 1.9, 2 to 5, >5 cm), and axillary lymph node
status (binary – yes/no or 0, 1 to 3, 4 to 10, >11 positive) were
estimated using the Cox proportional hazards model.
Unknown factors or those with missing data were excluded
from all model estimates. We used likelihood ratio testing to
evaluate whether variations in mortality risks by these catego-
ries were statistically significant. Hazard ratios (HRs) and their
associated 95% confidence intervals (CIs) were calculated as
estimates of relative risks of mortality [11,12]. Based on log-
log survival curves, proportional hazards assumption in these
data was validated for all categories of ER/PR status except
for ER-PR+. This is likely a consequence of ER-/PR+ being
the rarest ER/PR subtype, and for this subgroup, a gross vio-
lation of the proportional hazards assumption was not
observed. In our analyses, we evaluated age of diagnosis, year
of diagnosis, SEER registry site (stratified variable), race/eth-
nicity, histologic type, tumor size, stage, grade, and lymph
node status as potential confounders in multivariate Cox
regression modeling. We also evaluated the possible influ-
ence of initial cancer treatments (surgery/radiation – yes/no)
given that treatment recommendations are based on tumor
characteristics and that therapeutic interventions are associ-
ated with survival. We assessed whether associations
between ER/PR status and demographic/clinical characteris-
tics were different for varying levels of a factor by fitting inter-
action models. For each model, dummy variables were created
and each represented the combination of an ER/PR category
and the characteristic assessed, with ER+PR+ and the follow-
ing characteristics as referent categories: age less than 50
years, year of diagnosis 1990 to 1992, non-Hispanic white,
tumor grade 1, tumor stage 1, tumor size less than 2 cm,Available online http://breast-cancer-research.com/content/9/1/R6
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negative lymph nodes, and ductal tumor histology. Each full
model with the cross-categorized variables was compared to
the reduced model (main effects only) by likelihood ratio test-
ing to assess statistical significance. We also estimated
trends in HRs for each ER/PR profile and the following: (a) age
at diagnosis, per 5 years (30 to <35 years referent), (b) diag-
nosis year, per year (1990 referent), (c) tumor stage (stage 1
referent), (d) tumor size (0 to <1 cm [referent], 1 to <2, 3 to
<4, 4 to <5, 5 to <10, ≥10), (e) axillary nodal positivity (0 [ref-
erent], 1 to 3, 4 to 10, ≥11), and (f) tumor grade (grade 1 ref-
erent). These variables were treated as continuous variables
for trend estimates. All statistical tests were two-sided, and p
values of 0.05 or less were considered significant.
Results
Within the identified cohort of 155,175 women with known
joint ER/PR receptor status, 98,463 cases had ER+/PR+
tumors (63%). Of the remaining women, 19,886 cases had
ER+/PR- tumors (13%), 4,896 cases had ER-/PR+ tumors
(3%), and 31,930 cases had ER-/PR- tumors (21%). Older
women were more likely to be diagnosed with ER+/PR+
tumors, whereas more than one third of women 30 to 39 years
old presented with ER-/PR- tumors (Table 1). The proportion
of tumors that were ER+/PR+ increased over the study period,
whereas the proportions of tumors that were ER+/PR- and
ER-/PR- held fairly constant, and the proportion of tumors that
were ER-/PR+ declined. In general, for the other characteris-
tics shown in Table 1, ER+/PR+ and ER+/PR- tumors were
similar to each other and ER-/PR+ and ER-/PR- tumors were
similar to each other. Specifically, compared to women with
ER+PR+ and ER+/PR- tumors, those diagnosed with ER-/
PR+ and ER-/PR- tumors were somewhat more likely to be
younger and African-American, to have larger tumors, more
advanced disease stage, and higher tumor grade, and to
present with axillary lymph node metastases. In addition,
women with ER-/PR+ and ER-/PR- tumors were somewhat
less likely to have lobular, ductal/lobular, mucinous, or tubular
carcinomas and were somewhat more likely to have inflamma-
tory, comedo, or medullary carcinomas.
The risks of breast cancer-specific mortality were elevated
among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors
relative to women with ER+/PR+ tumors across all subcatego-
ries of age at cancer diagnosis (Table 2). Age was an effect
modifier of the relationship between ER/PR status and relative
risk of breast cancer mortality (p = 0.03). Specifically, HRs for
ER-/PR+ and ER-/PR- disease were particularly high among
women 65 years of age and older. For each 5-year increase in
age, a 5% to 7% elevation in mortality risk was observed within
each ER/PR profile (p for trend < 0.0001, all profiles) (Table
3). Among the population of women with ER-/PR- tumors rel-
ative to women with ER+/PR+ tumors, a higher relative mor-
tality risk was associated with a tumor diagnosed in the most
recent years versus a tumor diagnosed in the early 1990s (p
for interaction < 0.0001). However, decreases in HRs ranging
from 4% to 8% per year were observed with increasing calen-
dar year within each ER/PR profile and the magnitude of this
reduction was greater among women with ER+ disease than
ER- disease. In general, the magnitudes of the HRs associated
with each ER/PR profile were comparable across race/ethnic-
ity classifications (p for interaction = 0.77).
Elevations in breast cancer mortality risks were observed
among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors
relative to women with ER+/PR+ tumors across the majority of
clinical characteristics examined (Table 2). The magnitudes of
these relative risks did not vary appreciably by stage; also, for
each increase in tumor stage level, two-fold or greater
increases in mortality risks were observed within each ER/PR
profile (p for trend < 0.0001) (Table 3). Tumor size, lymph
node status, histology, and grade appeared to modify the rela-
tionship between ER/PR status and relative risk of mortality.
For tumor size and grade, the mortality risks associated with
ER-/PR+ tumors were particularly high among women whose
tumors were either more than 5 cm in size or of high grade. The
mortality risks associated with ER-/PR- tumors, relative to
ER+/PR+ tumors, were particularly high among women
whose tumors were less than 2 cm in size or of low grade
(Table 2). In addition, the HRs increased with increasing tumor
size, number of axillary lymph node metastases, and disease
grade within each ER/PR profile (p for trend < 0.0001, all pro-
files) (Table 3). The magnitude of the associated relative mor-
tality risk depended on ER/PR status. For example, women
with ER-/PR- tumors had a 24% increase in the relative risk of
breast cancer mortality with each increase in tumor grade
level, whereas women with ER+/PR+ tumors had a 62% ele-
vated mortality risk with each increase in tumor grade level.
With respect to histology, compared to women with ER+/PR+
tumors, women with ER+/PR- tumors had elevated risks of
mortality if their tumor was ductal or lobular, women with ER-/
PR+ tumors had elevated risks of mortality if their tumor was
ductal or inflammatory, and women with ER-/PR- tumors had
elevated risks of mortality across all histologies, except for
medullary carcinoma. Due to the sparse number of subjects in
each hormonal category and limited or no recorded deaths,
data were not shown for mucinous, papillary, and tubular
carcinomas.
Discussion
Previous studies have shown survival advantages among
women with hormone receptor-positive tumors relative to
women with hormone receptor-negative tumors [6,9,13-16]. A
recent study by Grann and coworkers [17] that also used data
collected from the SEER program reported that joint ER/PR
status was an independent predictor of outcome in a large
cohort of women with breast carcinoma. Our study expands
on this study, further evaluating the association between ER/
PR status and breast cancer-specific mortality within sub-
groups of women defined by personal characteristics (includ-
ing race/ethnicity, age at cancer diagnosis, and year of cancerBreast Cancer Research    Vol 9 No 1    Dunnwald et al.
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Table 1
Selected characteristics among breast cancer cases by hormone receptor status: SEER program, 1990–2001
ER+PR+ ER+PR- ER-PR+ ER-PR-
(n = 98,463) (n = 19,886) (n = 4,896) (n = 31,930)
Characteristics n Column % Row % n Column % Row % n Column % Row % n Column % Row %
Age at diagnosis, years
30–39 4,903 5.0 49.5 885 4.5 8.9 569 11.6 5.7 3,558 11.1 35.9
40–49 18,575 18.9 60.9 2,490 12.5 8.2 1,508 30.8 4.9 7,929 24.8 26.0
50–59 21,807 22.1 61.4 4,464 22.5 12.5 1,161 23.7 3.3 8,094 25.4 22.8
60–69 22,019 22.4 65.9 4,752 23.9 14.2 801 16.4 2.4 5,856 18.3 17.5
70–79 20,667 21.0 68.2 4,662 23.4 15.4 584 11.9 1.9 4,401 13.8 14.5
≥80 10,492 10.6 67.7 2,633 13.2 17.0 273 5.6 1.8 2,092 6.6 13.5
Diagnosis year
1990–1992 16,500 16.8 61.6 3,751 18.9 14.0 1,111 22.7 4.1 5,435 17.0 20.3
1993–1995 22,087 22.4 61.7 4,514 22.7 12.6 1,485 30.3 4.1 7,728 24.2 21.6
1996–1998 27,734 28.2 64.2 5,239 26.3 12.1 1,367 27.9 3.2 8,884 27.8 20.5
1999–2001 32,142 32.6 65.2 6,382 32.1 12.9 933 19.1 1.9 9,883 31.0 20.0
SEER registry
Atlanta, GA 5,696 5.8 59.4 1,171 5.9 12.2 381 7.8 4 2,344 7.3 24.4
Connecticut 11,093 11.3 61.4 2,448 12.3 13.6 602 12.3 3.3 3,914 12.3 21.7
Detroit, MI 10,559 10.7 60.4 2,314 11.6 13.2 539 11 3.1 4,063 12.7 23.3
Hawaii 4,149 4.2 67.0 703 3.5 11.3 273 5.6 4.4 1,072 3.4 17.3
Iowa 10,238 10.4 65.2 1,914 9.6 12.2 530 10.8 3.4 3,017 9.4 19.2
Los Angeles, CA 15,586 15.8 61.4 3,399 17.1 13.4 919 18.8 3.6 5,491 17.2 21.6
New Mexico 4,066 4.1 61.8 885 4.5 13.5 193 3.9 2.9 1,435 4.5 21.8
San Francisco-Oakland, CA 13,063 13.3 63.9 2,750 13.8 13.5 652 13.3 3.2 3,957 12.4 19.4
San Jose, CA 5,474 5.5 65.3 1,134 5.7 13.5 228 4.7 2.7 1,548 4.9 18.5
Seattle, WA 14,241 14.5 68 2,517 12.7 12.0 423 8.6 2.0 3,770 11.8 18.0
Utah 4,298 4.4 66.9 651 3.3 10.1 156 3.2 2.5 1,319 4.1 20.5
Race
Non-Hispanic white 78,805 81.7 65.4 15,716 80.5 13.0 3,515 73.5 2.9 22,532 72.1 18.7
African-American 5,724 5.9 48.0 1,488 7.6 12.5 504 10.5 4.2 4,206 13.5 35.3
Native American 284 0.3 55.0 57 0.3 11.0 23 0.5 4.5 152 0.5 29.5
Asian/Pacific Islander 6,065 6.3 65.1 1,061 5.4 11.4 382 8.0 4.1 1,805 5.8 19.4
Hispanic white 5,585 5.8 57.8 1,203 6.2 12.4 359 7.5 3.7 2,524 8.1 26.1
Other/Unknown 2,000 - - 361 - - 113 - - 711 - -
Tumor histology
Ductal 71,199 72.3 62.7 13,981 70.3 12.3 3,641 74.4 3.2 24,722 77.4 21.8
Lobular 8,980 9.1 73.6 2,160 10.9 17.7 283 5.8 2.3 784 2.5 6.4Available online http://breast-cancer-research.com/content/9/1/R6
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Ductal/Lobular 7,576 7.7 76.7 1,341 6.7 13.6 233 4.8 2.4 722 2.3 7.3
Inflammatory 543 0.5 37.8 191 1.0 13.3 90 1.8 6.3 611 1.9 42.6
Mucinous 2,927 3.0 80.9 486 2.4 13.5 41 0.8 1.1 164 0.5 4.5
Tubular 1,696 1.7 79 327 1.6 15.2 44 0.9 2.1 79 0.3 3.7
Comedo 1,159 1.2 43.6 318 1.6 12.0 179 3.6 6.7 1,003 3.1 37.7
Medullary 266 0.3 14.7 148 0.8 8.2 97 2.0 5.4 1,292 4.0 71.7
Papillary 582 0.6 79.0 58 0.3 7.9 10 0.2 1.3 87 0.3 11.8
Other 3,535 3.6 49.4 876 4.4 12.2 278 5.7 3.9 2,466 7.7 34.5
Tumor stage
I 50,172 52.4 69.2 9,232 48 12.7 1,999 42.7 2.8 11,114 36.2 15.3
II 37,335 39.0 60.3 7,606 39.5 12.3 2,068 44.2 3.3 14,878 48.4 24.1
III 5,332 5.5 51.3 1,471 7.6 14.1 385 8.2 3.7 3,210 10.4 30.9
IV 2,943 3.1 52.1 936 4.9 16.6 230 4.9 4.1 1,536 5.0 27.2
Unstaged 2,681 - - 641 - - 214 - - 1,192 - -
Tumor grade
1 18,012 21.8 81.1 2,885 17.5 13.0 405 9.9 1.8 914 3.3 4.1
2 40,642 49.3 74.2 7,133 43.4 13.0 1,324 32.5 2.4 5,682 20.6 10.4
3 22,082 26.8 44.4 6,027 36.6 12.1 2,174 53.3 4.4 19,412 70.4 39.1
4 1,774 2.1 45.0 413 2.5 10.5 173 4.3 4.4 1,579 5.7 40.1
Unknown 15,953 - 3,428 - 820 - 4,343 -
Tumor size (cm)
0–1.9 56,547 59.9 69.2 10,302 54.6 12.6 2,271 49.5 2.8 12,576 41.8 15.4
2–5 32,977 34.9 58.7 7,135 37.8 12.7 1,891 41.3 3.4 14,147 47.1 25.2
>5 4,949 5.2 48.8 1,432 7.6 14.1 422 9.2 4.2 3,330 11.1 32.9
Unknown 3,990 - - 1,017 - - 312 - - 1,877 - -
Axillary lymph node status
Negative 54,948 65.3 64.8 10,428 63.0 12.3 2,622 61.0 3.1 16,749 60.3 19.8
Positive 29,234 34.7 60.9 6,110 37.0 12.7 1,675 39.0 3.5 11,015 39.7 22.9
Unknown 14,281 - - 3,348 - - 599 - - 4,166 - -
Surgical treatment
Performed 96,387 98.0 63.7 19,216 96.7 12.7 4,764 97.4 3.2 30,847 96.8 20.4
Not performed 2,012 2.0 52.7 648 3.3 17.0 126 2.6 3.3 1,032 3.2 27
U n k n o w n 6 4 -- 2 2 -- 6 -- 5 1 --
Radiation therapy
Treated 46,859 48.5 65.5 8,694 44.5 12.1 2,048 42.9 2.9 13,922 44.8 19.5
None 49,776 51.5 61.9 10,836 55.5 13.4 2,725 57.1 3.4 17,131 55.2 21.3
Unknown 1,828 - - 356 - - 123 - - 877 - -
ER, estrogen receptor; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
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Table 2
Breast cancer mortality risk by hormone receptor status among women of different diagnosis age, race/ethnicity, diagnosis year, 
tumor stage, grade, histology, and axillary lymph node positivitya
ER+/PR+ ER+/PR- ER-/PR+ ER-/PR-
(n = 98,463) (n = 19,886) (n = 4,896) (n = 31,930)
Characteristics No. at 
risk
No. 
deaths
HR No. at 
risk
No. 
deaths
HR 95% CI No. at 
risk
No. 
deaths
HR 95% CI No. at 
risk
No. 
deaths
HR 95% CI p value for 
interaction
All casesb 98,463 7,319 1.0 19,886 2,434 1.4 1.3–1.5c 4,896 848 1.8 1.6–1.9c 31,930 6,300 2.3 2.2–2.4c
Age at 
diagnosis, yearsd
<50 16,962 1,042 1.0 2,387 245 1.2 1.1–1.4c 1,430 209 1.6 1.4–1.9c 8,056 1,323 2.1 1.9–2.3c
50–64 23,467 1,104 1.0 4,745 416 1.5 1.3–1.7c 1,072 124 1.5 1.2–1.8c 7,651 1,214 2.3 2.1–2.5c
≥65 25,078 1,496 1.0 5,563 540 1.5 1.3–1.7c 718 119 2.1 1.8–2.6c 5,536 1,020 2.6 2.4–2.8c 0.03
Diagnosis yeare
1990–1992 8,298 1,285 1.0 1,889 419 1.3 1.2–1.5c 597 146 1.6 1.3–1.9c 2,850 831 1.7 1.5–1.9c
1993–1995 13,665 1,348 1.0 2,688 428 1.5 1.3–1.7c 944 160 1.5 1.2–1.8c 4,859 1,234 2.2 2.0–2.4c
1996–1998 19,350 837 1.0 3,493 282 1.5 1.3–1.7c 971 121 2.1 1.7–2.6c 6,181 1,059 2.8 2.5–3.1c
1999–2001 24,194 172 1.0 4,625 69 1.6 1.2–2.1c 708 25 3.6 2.3–5.1c 7,353 433 4.9 4.1–6.0c <0.001
Race/Ethnicityf
Non-
Hispanic 
white
53,397 2,831 1.0 10,187 916 1.5 1.3–1.6c 2,396 313 1.8 1.6–2.0c 15,371 2,462 2.3 2.2–2.5c
African-
American
3,536 348 1.0 907 125 1.2 1.0–1.5c 293 60 1.7 1.3–2.2c 2,734 615 2.2 1.9–2.6c
Native 
American
196 19 1.0 34 11 1.5 0.5–3.8 12 1 1.7 0.1–16.4 102 25 3.4 1.5–7.3c
Asian/Pacific 
Islander
4,497 189 1.0 748 63 1.8 1.3–2.4c 267 34 1.6 1.1–2.4c 1,273 166 2.3 1.8–2.8c
Hispanic 
white
3,881 255 1.0 819 83 1.3 1.0–1.7c 252 44 1.9 1.3–2.6c 1,763 289 2.3 1.9–2.8c 0.77
Tumor stageg
I 33,821 487 1.0 6,038 146 1.4 1.2–1.7c 1,369 51 1.6 1.2–2.1c 7,704 391 2.3 2.0–2.7c
II 27,363 2,110 1.0 5,472 674 1.4 1.3–1.6c 1,529 248 1.6 1.4–1.9c 11,051 2,069 2.3 2.2–2.5c
III 3,410 659 1.0 922 252 1.3 1.2–1.6c 245 104 2.1 1.7–2.6c 1,940 763 2.3 2.0–2.6cAvailable online http://breast-cancer-research.com/content/9/1/R6
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IV 672 302 1.0 192 102 1.3 1.0–1.6c 59 42 1.9 1.3–2.7c 357 245 2.3 1.9–2.8c 0.45
Tumor size (cm)h
0–1.9 39,418 865 1.0 6,957 243 1.4 1.2–1.6c 1,607 91 1.5 1.2–1.9c 8,799 715 2.6 2.3–2.9c
2–5 22,579 2,081 1.0 4,781 708 1.5 1.3–1.6c 1,331 253 1.8 1.5–2.0c 10,214 2,019 2.2 2.1–2.4c
>5 2,718 526 1.0 761 206 1.3 1.1–1.6c 217 89 2.2 1.7–2.7c 1,730 636 2.2 1.9–2.5c <0.001
Axillary lymph 
node statusi
Negative 42,451 942 1.0 7,924 324 1.6 1.4–1.8c 1,898 114 2.0 1.6–2.4c 12,541 1,006 2.8 2.6–3.1c
1–3 14,953 1,021 1.0 2,828 324 1.5 1.3–1.7c 790 133 1.8 1.5–2.1c 4,857 977 2.5 2.3–2.7c
4–10 5,313 861 1.0 1,133 277 1.4 1.2–1.6c 332 108 1.7 1.3–2.1c 2,268 793 2.4 2.2–2.7c
≥11 2,549 734 1.0 739 249 1.2 1.0–1.4c 182 90 1.7 1.3–2.1c 1,386 692 2.2 1.9–2.4c 0.08
Tumor histologyj
Ductal 52,178 2,919 1.0 9,978 994 1.5 1.4–1.6c 2,711 390 1.8 1.6–2.0c 18,542 3,040 2.3 2.2–2.5c
Lobular 3,975 186 1.0 938 64 1.4 1.0–1.9c 123 3 0.4 0.1–1.4 325 47 1.9 1.4–2.7c
Ductal/
Lobular
5,472 254 1.0 929 59 1.3 0.9–1.7 148 13 1.1 0.6–2.0 511 83 2.7 2.1–3.5c
Inflammatory 241 52 1.0 77 22 1.4 0.8–2.3 39 19 3.4 1.9–6.1c 258 123 3.5 2.4–5.0c
Comedo 652 91 1.0 187 19 0.6 0.4–1.1 91 16 1.2 0.7–2.1 556 109 1.6 1.2–2.1c
Medullary 120 14 1.0 73 6 0.7 0.2–2.2 48 4 0.9 0.2–3.0 716 54 0.7 0.4–1.4 <0.001
Tumor gradek
1 13,854 156 1.0 2,141 40 1.6 1.1–2.3c 310 6 1.0 0.4–2.5 661 32 2.6 1.7–3.9c
2 32,661 1,349 1.0 5,555 374 1.5 1.3–2.1c 1,074 95 1.7 1.3–2.1c 4,312 575 3.1 2.8–3.4c
3 17,352 1,873 1.0 4,613 710 1.3 1.2–1.5c 1,694 319 1.7 1.5–1.9c 14,967 2,635 2.1 1.9–2.2c
4 1,399 180 1.0 315 50 1.4 1.0–2.0c 124 25 2.1 1.4–3.3c 1,112 226 2.3 1.8–2.8c <0.001
aThe reference ER/PR profile for all analyses was ER+/PR+. bHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation 
treatment, and lymph node status (positive/negative). cp < 0.05. dHRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation 
treatment, and lymph node status (positive/negative). eHRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and 
lymph node status (positive/negative). fHRs adjusted for age and year at diagnosis, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node 
status (positive/negative). Race unknown, n = 3,185. gHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and 
surgical and radiation treatment. Stage unknown, n = 4,728. hHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status 
(categorical), and surgical and radiation treatment. Size unknown, n = 7,196. iHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and 
surgical and radiation treatment. Nodal status unknown, n = 22,394. jHRs adjusted for age and year at diagnosis, race, SEER registry, tumor grade, stage, lymph node status 
(categorical), and surgical and radiation treatment. Other/unknown histology, n = 7,155. kHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, 
lymph node status (categorical), and surgical and radiation treatment. Grade unknown, n = 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, 
progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
Table 2 (Continued)
Breast cancer mortality risk by hormone receptor status among women of different diagnosis age, race/ethnicity, diagnosis year, 
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diagnosis) and tumor characteristics (including histology,
stage, grade, size, and axillary lymph node metastases). In gen-
eral, we observed that the higher relative risks of mortality
associated with having an ER+/PR-, an ER-/PR+, or an ER-/
PR- tumor relative to an ER+/PR+ tumor were consistently
present across almost all tumor characteristics. Even among
women with poor prognoses, such as those with stage IV dis-
ease, multiple positive lymph nodes, or tumors of high grade,
differences in the relative risk of mortality by ER/PR status
were observed. We also estimated mortality trends by ER/PR
status within the study population. Within each ER/PR profile,
we document an increase in the relative risk of breast cancer
mortality for each 5-year increase in age and for each incre-
mental increase in tumor stage, size, grade, or axillary lymph
node metastases. These findings are in agreement with the
known correlation between increased breast cancer mortality
risk and increasing tumor stage, size, grade, or regional lymph
node metastases [18,19]. We observed a decreased mortality
trend each year over the study period of 1990 to 2001 which
was greatest in magnitude among women with ER+ tumors.
This trend may be related to improvements in breast cancer
treatments and/or early detection methods resulting in
improved patient outcomes.
We did observe some variations in the association between
ER/PR status and risk of breast cancer mortality by tumor size,
grade, and histology. Relative to ER+/PR+ patients, and within
subcategories of tumor size and grade, the highest observed
relative mortality risks were among ER-/PR- patients whose
tumors were small (0 to 1.9 cm) or of low grade (grade 1 and
2). These elevated risks are likely related to adjuvant treatment
standards given that hormonal therapy generally is recom-
mended for women with ER+/PR+ disease, regardless of
tumor size. Conversely, adjuvant chemotherapy is not routinely
recommended for ER-/PR- patients whose tumors are small
and have favorable features (that is, negative lymph nodes,
highly differentiated) [20]. Our data also showed that ER-/
PR+ patients whose tumors were more than 5 cm in size or of
high grade had particularly elevated relative mortality risks
(HRs = 2.2 and 2.1, respectively) that were higher than those
with ER+/PR- tumors of similar size and grade (HRs = 1.3 and
1.4, respectively), suggesting that ER negativity may have a
greater influence on mortality risk than PR negativity among
women with these tumor types. Compared to women with
ER+/PR+ tumors, those with ER-/PR- tumors had increased
risks of mortality across almost all histologic classifications,
suggesting that combined ER/PR negativity has implications
for relative mortality risk, regardless of tumor histology. The
one noted exception was that ER/PR status did not appear to
be related to the relative risk of mortality among women with
medullary carcinomas. Medullary carcinomas are rare, and
although they are typically high-grade, they tend to have well-
defined, distinct borders. Their prognosis is more favorable
than that of other invasive breast carcinomas, such as ductal
carcinoma [21].
Researchers who examined the risk of invasive breast carci-
noma diagnosis among women of different races reported that
certain ethnicities have elevated risks of presenting with ER-/
PR- tumors. African-Americans, Asians, Native Americans, and
Hispanic whites were found to have greater risks of presenting
with ER-/PR- breast tumors compared to non-Hispanic whites
[22-25]. Although it has been shown that women of certain
racial/ethnic groups have increased risks of developing hor-
Table 3
Trends in hazard ratios for breast cancer mortality associated with hormone receptor status and different demographic and clinical 
characteristics
ER+/PR+ ER+/PR- ER-/PR+ ER-/PR-
Characteristics HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age at diagnosis, per 5 yearsa 1.05 1.04–1.06 1.07 1.04–1.09 1.07 1.03–1.10 1.06 1.05–1.07
Diagnosis year, per yearb 0.93 0.92–0.94 0.92 0.90–0.94 0.95 0.91–0.98 0.96 0.95–0.97
Tumor stagec 2.33 2.20–2.46 2.29 2.09–2.51 2.55 2.19–2.96 2.06 1.94–2.18
Tumor size (cm)d 1.27 1.24–1.30 1.29 1.24–1.34 1.33 1.25–1.41 1.22 1.20–1.25
Axillary lymph node statuse 1.71 1.65–1.78 1.55 1.46–1.66 1.61 1.44–1.80 1.64 1.58–1.70
Tumor gradef 1.62 1.55–1.70 1.49 1.36–1.63 1.72 1.46–2.03 1.24 1.16–1.32
aFive-year categories. Reference = 30 to <35 years. HRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, 
surgical and radiation treatment, and lymph node status (positive/negative). bReference = 1990. HRs adjusted for age at diagnosis, race, SEER 
registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). cReference = stage 1. HRs 
adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Stage 
unknown, n = 4,728. dCategories = 0 to <1, 1 to <2, 2 to <3, 3 to <4, 4 to <5, 5 to <10, ≥10 cm. Reference = 0 to <1 cm. HRs adjusted for age 
and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Size unknown, n = 
7,196. eCategories = 0, 1 to 3, 4 to 10, ≥11. Reference = 0. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, 
stage, grade, and surgical and radiation treatment. Nodal status unknown, n = 22,394. fReference = grade 1. HRs adjusted for age and year at 
diagnosis, race, SEER registry, tumor histology, stage, lymph node status, and surgical and radiation treatment. Grade unknown, n = 24,544. CI, 
confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.Available online http://breast-cancer-research.com/content/9/1/R6
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mone receptor-negative tumors, our results show little or no
difference in mortality risks within ethnic classes for each ER/
PR profile. For example, African-American women whose
tumors were ER-/PR+ or ER-/PR- were found to have relative
risks of breast cancer mortality similar to non-Hispanic whites
with ER-/PR+ or ER-/PR- tumors, respectively.
There are potential study limitations using SEER data. First,
ER/PR status, tumor histology, and tumor grade were not
assessed centrally since the data recorded by SEER are
derived from review of clinical pathology reports. Most impor-
tantly, assays and techniques used for ER/PR testing likely var-
ied both across and within laboratories over the course of this
study. For example, cutoff points may have been dissimilar in
differentiating hormone receptor positivity. High cutoff values
may result in tumors being misclassified as ER- [26]. However,
assay techniques for ER and PR have improved since their
inception nearly 30 years ago and receptor status can be
appropriately determined with relative ease [27,28]. In the
period to which this study was restricted (1990 to 2001),
pathology laboratories in general routinely performed ER/PR
testing of breast cancer. Also reassuring is the fact that the
proportions of the four joint tumor ER/PR receptor profiles in
our study population were comparable to those reported in
other studies [13,14].
The exclusion of subjects with no recorded ER/PR data is a
second potential limitation of this study. The absence of
recorded hormone receptor data has been reported to be
associated with age and year of diagnosis, tumor stage, grade,
histology, and SEER registries [17,29], and thus the lack of
ER/PR data on these cases could bias our results. However,
the number of SEER records missing ER/PR data has
declined over time and the decline has been shown to be con-
sistent across all age categories [29]. The proportion of
records containing ER/PR data for this cohort increased over
time, ranging from 67.5% in 1990 to 73% in the years 1994
to 1995 and 80.7% in 2001, results that are consistent with
prior reports [17].
Survivorship for SEER registries is tracked through state vital
records and the National Death Index (NDI) established by the
National Center for Health Statistics (NCHS). Cause-of-death
data in relation to death certificate completion or coding are
subject to misclassification. However, US death certificates
are checked at several levels for completeness before trans-
mission to the NCHS. The NDI is reported to have the highest
sensitivity of all major US mortality databases [30]. In addition,
a study that evaluated the accuracy of the cause-of-death
code found small discrepancy rates (ranging from 4% to 7%)
between NDI Plus codes, final study codes, and NCHS nosol-
ogists' original codes [31].
The SEER program does not collect data regarding mammog-
raphy screening program participation within the designated
state and metropolitan tumor registries. Mammography
screening programs have been shown to improve patient out-
comes [32]. The decreased mortality trend we observed each
year over the study period, particularly among women with
ER+ tumors, may be due in part to screening programs.
A final limitation of this study is that SEER registries do not
provide data on the receipt of adjuvant or hormonal therapies
following primary surgical and/or radiotherapy interventions.
Treating hormone receptor-positive tumors with hormonal
therapies has been shown to be a contributing factor in better
survival among women with breast cancer [9]. A large propor-
tion of the survival advantage experienced by ER+/PR+
patients compared to ER-/PR- patients may be due to the use
of hormonal therapy. Our data indicate that in 1990 to 1992,
when the use of hormonal therapy had just begun, ER-/PR-
patients had a 1.7-fold greater relative risk of mortality;
however, by 1999 to 2001, when hormonal therapy was
widely integrated into clinical practice and guidelines for its
use were well established, women with ER-/PR- tumors had a
4.9-fold greater relative risk of mortality. In future years, the
advent of better chemotherapy treatments for the ER- patient
population may result in improved disease-free survival and
overall survival. Recent studies have reported that the large
survival differences among ER+ patients treated with hormo-
nal therapy versus ER- patients treated with chemotherapy
have dwindled and that ER- patients are now deriving a greater
benefit from improved chemotherapy regimens with risk reduc-
tions as high as 49% [33,34].
Conclusion
Overall, our findings suggest that the higher risks of mortality
in women with ER+/PR-, ER-/PR+, and ER-/PR- tumors, com-
pared to women with ER+/PR+ tumors, are largely independ-
ent of the various demographic and clinical tumor
characteristics assessed in this study. This indicates that the
prognostic utility of ER/PR status is for the most part inde-
pendent of these other factors. However, the strength of the
associations we assessed did vary within subcategories of
certain factors. The higher relative mortality risks we identified
among ER-/PR- patients with small or low-grade tumors raise
the question of whether there may be a beneficial role for adju-
vant chemotherapy in this population. The lack of data on adju-
vant chemotherapies from SEER limits our ability to make this
determination. Other underlying biological factors may
account for the observed variations in tumor hormone receptor
status and mortality risk, requiring additional research to be
conducted.
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